-- Mineralys Therapeutics (MLYS) has an average rating of buy and mean price target of $49.38, according to analysts polled by FactSet.
(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)